文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.

作者信息

Beigel John H, Tomashek Kay M, Dodd Lori E

机构信息

National Institute of Allergy and Infectious Diseases, Bethesda, MD

出版信息

N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.

DOI:10.1056/NEJMc2022236
PMID:32649078
Abstract
摘要

相似文献

[1]
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.

N Engl J Med. 2020-9-3

[2]
Remdesivir for the Treatment of Covid-19 - Preliminary Report.

N Engl J Med. 2020-9-3

[3]
Remdesivir for the Treatment of Covid-19 - Preliminary Report.

N Engl J Med. 2020-9-3

[4]
Remdesivir for the Treatment of Covid-19 - Preliminary Report.

N Engl J Med. 2020-9-3

[5]
Remdesivir for the Treatment of Covid-19 - Preliminary Report.

N Engl J Med. 2020-9-3

[6]
[Remdesivir for patients with COVID-19].

Internist (Berl). 2020-8

[7]
Compassionate Use of Remdesivir in Covid-19. Reply.

N Engl J Med. 2020-6-18

[8]
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.

Int J Antimicrob Agents. 2020-4

[9]
Efficacy of Remdesivir in COVID-19.

JAMA. 2020-9-15

[10]
Remdesivir and COVID-19 - Authors' reply.

Lancet. 2020-10-3

引用本文的文献

[1]
[Multisystemic inflammatory syndrome in children with COVID-19: a rheumatology perspective].

Rev Colomb Reumatol. 2021

[2]
Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19.

Clin Pharmacokinet. 2025-5

[3]
Factors of progression to severity and death in COVID-19 patients at two health care sites in Bamako, Mali.

BMC Infect Dis. 2025-1-17

[4]
Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China.

BMC Nephrol. 2025-1-16

[5]
Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses.

Int J Chron Obstruct Pulmon Dis. 2024

[6]
A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies.

Stat Methods Med Res. 2024-11

[7]
High-Dose or Low-Dose Corticosteroids - Which Regimen is More Effective in Patients with Moderate to Severe COVID-19? A Retrospective Study.

Maedica (Bucur). 2024-6

[8]
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.

Clin Pathol. 2024-7-26

[9]
Efficacy of Remdesivir on Clinical Outcomes in COVID-19 Patients: A Study in a Tertiary Care Hospital in Pakistan.

J Community Hosp Intern Med Perspect. 2024-5-7

[10]
Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana.

Open Forum Infect Dis. 2024-7-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索